Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types.

CAS：319460-85-0
中文别名：N-甲基-2-((3-((1E)-2-(吡啶-2-基)乙烯)-1H-吲唑-6-基)硫)苯甲酰胺;AXI锡IB;
英文别名：AG-013736 N-Methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide;AVERMECTINB;[14C]-Axitinib;Axtinib;Inlyta;10mg;AXITINIB;Axitinib (usan);
分子式：C22H18N4OS
分子量：386.47
精确质量：386.12
Psa：95.97
Logp：5.03

MDL号：MFCD09837898

外观与性状：灰白色固体
密度：1.35 g/cm3
沸点：668.9ºC at 760 mmHg
熔点：213-215ºC
闪点：358.3ºC
折射率：1.728

海关编码：2933990090
信号词：Warning
危险性描述：H302; H400
危险性防范说明：P273
危险标志：GHS07, GHS09

用途
阿西替尼一种主要靶向于VEGFR酪酸激酶、抑制血管生成的小分子抗癌药。